Clinical Trial: NCT01940276
Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Duke University |
| Information Provided By: | Duke University |
| Last Update Posted: | 2020-12-09 |
Study Overview
Brief Summary
The primary goal is to prospectively estimate the median radiographic PFS of African American and Caucasian men with mCRPC to abiraterone acetate and prednisone.
Official Title
A Phase II Open-label, Parallel Group Study of Abiraterone Acetate Plus Prednisone in African American and Caucasian Men With Metastatic Castrate-resistant Prostate Cancer
Conditions
Prostate Cancer
Intervention / Treatment
- Drug: Abiraterone acetate
- Drug: Prednisone
Other Study ID Numbers
- Pro00046383
- 212082PCR2018
Start Date (Actual)
2013-10
Primary Completion Date (Actual)
2019-10-08
Study Completion Date (Actual)
2019-10-08
Enrollment (Actual)
100
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Duke University |
| Information Provided By: | Duke University |
| Last Update Posted: | 2020-12-09 |
Study Overview
Brief Summary
The primary goal is to prospectively estimate the median radiographic PFS of African American and Caucasian men with mCRPC to abiraterone acetate and prednisone.
Official Title
A Phase II Open-label, Parallel Group Study of Abiraterone Acetate Plus Prednisone in African American and Caucasian Men With Metastatic Castrate-resistant Prostate Cancer
Conditions
Prostate Cancer
Intervention / Treatment
- Drug: Abiraterone acetate
- Drug: Prednisone
Other Study ID Numbers
- Pro00046383
- 212082PCR2018
Start Date (Actual)
2013-10
Primary Completion Date (Actual)
2019-10-08
Study Completion Date (Actual)
2019-10-08
Enrollment (Actual)
100
Study Type
Interventional
Phase
Phase 2